Back

Design and baseline data of AZURE-HeFH, a phase 3 study assessing the effect of the oral PCSK9 inhibitor laroprovstat on LDL cholesterol in patients with heterozygous familial hypercholesterolaemia

29 August 2026 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: Emerging lipid-lowering therapeutic modalities Lipid-Lowering Agents ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Erik Stroes

AmsterdamUMC location AMC, Amsterdam (Netherlands (The))

5 More presentations in this session

Presentation thumbnail
Apolipoprotein and inflammatory biomarker changes following marked triglyceride reduction with the GalNAc-conjugated APOC3 siRNA RBD5044
Ms S. Nilsson (Gothenburg, SE)
Abstract
Presentation thumbnail
RNA targeted therapies for lipoprotein(a) lowering: systematic review and meta analysis of siRNA and antisense oligonucleotides
Doctor B. Buot (Quezon City, PH)
Abstract
Presentation thumbnail
Dose-related effects of olezarsen in hypertriglyceridaemia: a systematic review and meta-analysis of 2,610 patients
Miss S. Martinez-Topete (Tijuana, MX)
Abstract
Presentation thumbnail
Comparative effectiveness of probucol versus ezetimibe in statin-treated patients with established atherosclerotic cardiovascular disease
Doctor L. Liu (Tianjin, CN)
Abstract
Presentation thumbnail
Evolocumab early reduces Interleukin-1β/Interleukin-17A and improves left ventricular function in ST-segment elevation myocardial infarction: an observational study in the real world
Professor J. Gao (Tianjin, CN)
Abstract

Access the full session

Session thumbnail
Emerging lipid-lowering therapeutic modalities

The Event

Event poster

ESC Congress 2026

29 August 2026 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Effectiveness of PCSK9 inhibitors in homozygous familial hypercholesterolemia: insights from a Saudi Arabia genetic population
3 April 2025
thumbnail
Congress Presentation
REDUCE-IT: outcomes by baseline statin type
28 August 2020
thumbnail
Congress Presentation
Blood pressure and LDL-cholesterol control in patients with primary hypertension is far from optimal: results from a large observational, multicentric, prospective study
1 September 2019
thumbnail
Congress Presentation
LIBerate-HeFH - a novel PCSK9-inhibitor in heterozygous FH
28 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources